FDA supplemental approval: Oxycodone Hydrochloride (REMS)

AI Summary

The FDA approved a supplemental REMS application for oxycodone hydrochloride tablets (5 mg, 15 mg, 20 mg, and 30 mg) submitted by Novel Labs Inc. on 18 June 2026. This is a regulatory compliance action governing risk management conditions; it does not contain clinical efficacy or safety trial data.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for oxycodone hydrochloride tablets; this is a regulatory action, not a clinical trial, and does not report efficacy or safety trial outcomes.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This regulatory approval addresses REMS conditions for oxycodone dispensing and use; clinicians should ensure familiarity with current REMS requirements. No new efficacy or safety data are provided by this record.

Caveats

• This record does not contain clinical trial results, efficacy data, or comparative safety analysis.
• REMS requirements and details are not specified in this record; refer to the full FDA REMS documentation for prescribing and dispensing conditions.
• The record does not specify what aspects of the REMS were updated or supplemented.
• No patient population, sample size, or outcome measures are reported.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.